Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

Recent & Breaking News (TSXV:XRTX)

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

GlobeNewswire November 28, 2022

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire November 25, 2022

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

GlobeNewswire November 16, 2022

XORTX Presents New Proof of Concept Data at American Society of Nephrology

GlobeNewswire November 3, 2022

XORTX Announces Participation at Upcoming Investor Conferences

GlobeNewswire November 3, 2022

XORTX Receives Further No Objection Letter from Health Canada

GlobeNewswire October 26, 2022

XORTX Sponsored American Society of Nephrology Study Abstract Available Online

GlobeNewswire October 25, 2022

XORTX (TSXV:XRTX) closes US$5M public offering

John Ballem  October 11, 2022

XORTX Announces Closing of US$5 Million Public Offering

GlobeNewswire October 7, 2022

XORTX (TSXV:XRTX) announces US$5M public offering

John Ballem  October 4, 2022

XORTX Announces US$5 Million Public Offering

GlobeNewswire October 4, 2022

XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

GlobeNewswire September 19, 2022

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology - Kidney Week 2022

GlobeNewswire September 1, 2022

XORTX (TSXV:XRTX) oral drug yields positive results

Caroline Egan  August 22, 2022

XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

GlobeNewswire August 22, 2022

XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration

GlobeNewswire August 4, 2022

XORTX Reports Annual & Special Meeting Results

GlobeNewswire July 22, 2022

XORTX (TSXV:XRTX) submits request to EMA for medicinal products for human use

Jonathon Brown July 19, 2022

XORTX Announces Submission to European Medicines Agency

GlobeNewswire July 19, 2022

XORTX (TSXV:XRTX) sees positive topline results from Pharmacokinetics Bridging Clinical Trial

Jonathon Brown July 13, 2022